文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

咽拭子和直肠拭子半定量培养可有效预测机械通气ESBL携带者的ESBL-肠杆菌相关呼吸机相关性肺炎

Semi-quantitative cultures of throat and rectal swabs are efficient tests to predict ESBL-Enterobacterales ventilator-associated pneumonia in mechanically ventilated ESBL carriers.
PubMed 文献 · Intensive Care Med · 2020-04-20
一句话结论在ICU携带非大肠埃希菌ESBL-E的患者中,咽部携带或直肠高密度携带是发生ESBL-E VAP的危险因素。

研究纳入2014年5月至2017年5月医疗ICU中365例ESBL-E携带者,对咽拭子和直肠拭子ESBL-E密度进行半定量评估。82例发生107次革兰阴性杆菌VAP,其中ESBL-E VAP 50次、非ESBL-E GNB-VAP 57次,中位机械通气13天后发生,VAP前中位5天采集的最近一次阳性拭子用于分析。ESBL-E大肠埃希菌携带者发生ESBL-E VAP的比例(34%)低于其他ESBL-E携带者(67.3%);ESBL-E VAP组咽拭子阳性率(78%)高于非ESBL-E GNB-VAP组(23%),且直肠拭子ESBL-E密度显著更高。多因素模型显示非大肠埃希菌ESBL-E携带和直肠ESBL-E携带密度或咽部携带与ESBL-E VAP独立相关。

要点

  • 在365例ESBL-E携带者中,82例发生107次GNB-VAP,ESBL-E VAP 50次、非ESBL-E GNB-VAP 57次,中位机械通气13天后发生。
  • ESBL-E大肠埃希菌携带者发生ESBL-E VAP为13例(34%),低于其他ESBL-E携带者的32例(67.3%)(p < .01)。
  • ESBL-E VAP组咽拭子阳性39例(78%),非ESBL-E GNB-VAP组12例(23%)(p < .01)。
  • ESBL-E VAP与直肠拭子ESBL-E密度显著更高相关。
  • 多因素模型中,非大肠埃希菌ESBL-E携带和直肠ESBL-E携带密度、或咽部携带,仍与ESBL-E VAP相关。

适用人群与场景

  • 医疗ICU中携带产超广谱β-内酰胺酶肠杆菌(ESBL-E)且临床怀疑革兰阴性杆菌呼吸机相关性肺炎(GNB-VAP)的机械通气患者。
  • 研究纳入2014年5月至2017年5月期间的ESBL-E携带者,中位机械通气13天后发生GNB-VAP。

诊断标准与关键阈值

  • GNB-VAP诊断依据支气管肺泡灌洗或防污染 telescope 导管采样,定量培养有显著意义。
  • 用于预测的拭子为GNB-VAP发生前至少48小时采集的最近一次阳性咽拭子或直肠拭子,中位为VAP发生前5天。

研究设计与关键结果

  • 研究类型为在医疗ICU开展的研究,数据来自前瞻性收集的数据库;365例ESBL-E携带者中82例发生107次GNB-VAP(ESBL-E VAP 50次,非ESBL-E GNB-VAP 57次),中位机械通气13天后发生。
  • VAP发生前抗菌药物使用两组相似;最近一次拭子中位在VAP发生前5天采集。
  • ESBL-E大肠埃希菌携带者发生ESBL-E VAP 13例(34%),其他ESBL-E携带者32例(67.3%),p < .01。
  • ESBL-E VAP组咽拭子阳性39例(78%),非ESBL-E GNB-VAP组12例(23%),p < .01。
  • ESBL-E VAP与直肠拭子ESBL-E密度显著更高相关。
  • 多因素模型中,非大肠埃希菌ESBL-E携带和直肠ESBL-E携带密度、或咽部携带,仍与ESBL-E VAP相关。

证据类型、等级与局限

  • 证据类型:基于前瞻性收集数据库的分析性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对ICU中携带非大肠埃希菌ESBL-E且怀疑GNB-VAP的机械通气患者,咽部ESBL-E携带或直肠高密度ESBL-E携带是ESBL-E VAP的危险因素,可帮助判断经验性抗菌是否需覆盖ESBL-E。
  • ESBL-E大肠埃希菌携带者发生ESBL-E VAP的比例较低(34% vs 67.3%),在该亚组中依据拭子结果决策时需注意其预测价值可能不同。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: In ICU patients with carriage of extended spectrum beta-lactamase producing Enterobacterales (ESBL-E) and suspected Gram-negative bacilli ventilator-associated pneumonia (GNB-VAP), the quantification of the rectal and throat ESBL-E carriage might predict the ESBL-E involvement in GNB-VAP. Our aim was to evaluate whether a semi-quantitative assessment of rectal/throat ESBL-E carriage can predict ESBL-E-associated VAP in medical ICU patients.

METHODS: From May 2014 to May 2017, all ESBL-E carriers had a semi-quantitative assessment of ESBL-E density in swabs cultures. For those who developed GNB-VAP (diagnosed using bronchoalveolar lavage or plugged telescopic catheter with significant quantitative culture), the last positive swab collected at least 48 h before GNB-VAP onset was selected. Clinical data were extracted from a prospectively collected database.

RESULTS: Among 365 ESBL-E carriers, 82 developed 107 episodes of GNB-VAP (ESBL-E VAP, n = 50; and non-ESBL-E GNB-VAP, n = 57) after 13 days of mechanical ventilation in median. Antimicrobials use before VAP onset was similar between groups. The last swabs were collected 5 days in median before VAP onset. ESBL-E. coli carriers developed ESBL-E VAP less frequently (n = 13, 34%) than others (n = 32, 67.3%, p < .01). Throat swab positivity (39 (78%) vs. 12 (23%), p < .01) was more frequent for ESBL-E VAP. ESBL-E VAP was associated with significantly higher ESBL-E density in rectal swabs. In multivariate models, non-E. coli ESBL-E carriage and rectal ESBL-E carriage density, or throat carriage, remained associated with ESBL-E VAP.

CONCLUSION: In carriers of ESBL-E other than E. coli, ESBL-E throat carriage or a high-density ESBL-E rectal carriage are risk factors of ESBL-E VAP in case of GNB-VAP.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Andremont O, Armand-Lefevre L, Dupuis C, et al. Semi-quantitative cultures of throat and rectal swabs are efficient tests to predict ESBL-Enterobacterales ventilator-associated pneumonia in mechanically ventilated ESBL carriers. Intensive Care Med. 2020. PMID: 32313993. doi:10.1007/s00134-020-06029-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。